Postoperative recurrence is the main cause of primary treatment failure in the resectable non-small cell lung cancer (NSCLC). Systematic treatments should be taken to decrease the recurrence. Adjuvant chemotherapy, including neoadjuvant chemotherapy, postoperative adjuvant chemotherapy and targeted therapy, is a widely used in this area. In this review, we summarize the clinical trials and meta-analysis related to the adjuvant chemotherapy and targeted therapy in patients with early stage NSCLC.
肺癌患者术后复发转移是临床治疗失败的主要原因，因此亟待一种更系统的治疗手段来完善患者的治疗计划，以降低复发率、延长生存期。辅助化疗（包括新辅助化疗、术后辅助化疗、靶向药物辅助化疗）应运而生。本文就辅助治疗领域的研究进展进行综述。